Unlikely treatment linked with longer survival in breast cancer study
A recent U.S. study has found that estrogen creams, often used to treat menopause symptoms, are not only safe for older women diagnosed with breast cancer but may also be linked with longer survival.
The research, presented at the ASCO meeting, found that the use of the hormone creams by postmenopausal breast cancer survivors was associated with a lower risk of disease progression, recurrence, or death, rather than an increased risk as had been feared.
These findings contradict previous concerns that such creams might stimulate breast cancer cells that use hormones to grow.
Vaginal estrogen creams are commonly used to treat menopause symptoms, including vaginal dryness, discomfort, and pain during intercourse. However, many breast cancer survivors avoid these products.
Researchers reviewed national database records on 18,620 female breast cancer patients aged 65 and older who were diagnosed between 2010-2017, including 800 who used vaginal estrogen creams.
After accounting for patients' race, cancer stage, treatments and other factors, the researchers saw a statistically significant increase in overall survival among patients who used vaginal estrogen.
The cream users also had a significant increase in breast cancer-specific survival, the interval from diagnosis to death from breast cancer.
On average, estrogen cream users had a 47 per cent lower risk of dying from breast cancer and a 44 per cent lower risk of death from any cause during the study period, compared to non-users.
Even in patients whose tumours were known to use hormones for growth, estrogen cream use was associated with a 38 per cent lower risk of death from any cause.
Main symptoms of breast cancer in women
NHS
Estrogen cream users with hormone-positive breast cancer also had a lower risk of death from breast cancer, but that difference was not statistically significant.
Use of the creams for more than seven years appeared to confer an additional survival benefit.
'These findings add to a rising contemporary paradigm shift that local hormone therapy is not associated with increased risk to overall or breast cancer-specific survival, which has important clinical implications,' the researchers said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
30 minutes ago
- The Independent
Statins can reduce sepsis deaths, study suggests
People who are critically ill with sepsis may be more likely to survive if they are given statins, a new study suggests. Researchers wanted to explore whether the cholesterol-busting drugs may bring additional benefits for patients. The new study examined information on sepsis patients who received statins during a stint in intensive care and compared it with patients in a similar situation who did not receive statins. Some 14.3% of 6,000 sepsis patients who were given statins died within 28 days. This is compared with 23.4% of 6,000 patients who did not receive statin therapy. The research team from China said that this equates to a 39% reduced risk of death within a month. The research, based on data from thousands of patients at a hospital in Israel between 2008 and 2019, also found that 7.4% of statin patients died while in the intensive care unit compared with 13.6% of those who did not receive statins. And during their overall hospital stay, some 11.5% of sepsis patients who were given statins died, compared with 19.1% of sepsis patients who did not take statins. However, it appeared that those who were not prescribed statins had a slightly shorter hospital stay compared with those who did receive them – an average of eight days compared with almost 10 days. 'We found that statin users exhibited decreased 28-day all-cause mortality,' the authors wrote in the journal Frontiers in Immunology. Sepsis is a life-threatening reaction to an infection that occurs when the immune system overreacts and starts to damage the body's tissues and organs. In the UK, 245,000 people are affected by sepsis every year. UK sepsis experts said that 'anything which might reduce the burden of a condition which claims one in five lives worldwide needs to be rigorously explored' as they called for larger trials to confirm the findings. Statins are known as cholesterol-busting drugs because they can help lower the level of low-density lipoprotein (LDL) cholesterol in the blood. But experts said that they also have other benefits, including reducing inflammation and antibacterial effects. The research team called for larger trials to confirm their findings. 'Our large, matched cohort study found that treatment with statins was associated with a 39% lower death rate for critically ill patients with sepsis, when measured over 28 days after hospital admission,' said Dr Caifeng Li, the study's corresponding author and an associate professor at Tianjin Medical University General Hospital in China. 'These results strongly suggest that statins may provide a protective effect and improve clinical outcomes for patients with sepsis.' Commenting on the study, Dr Ron Daniels, founder and chief executive of the UK Sepsis Trust, said: 'It has been known for some time that the anti-inflammatory properties of statins confer a survival benefit on those who take them if they develop sepsis. 'Whilst previous studies have failed to show a similar survival benefit in treating people with sepsis with statins, this new study supports calls for a large, multi-country, randomised control trial. 'Anything which might reduce the burden of a condition which claims one in five lives worldwide needs to be rigorously explored.'
BBC News
an hour ago
- BBC News
Brighton GP surgery under threat from private company, says campaigner
Campaigners are holding a tug-of-war to highlight what they say is the threat to a community-run, non-profit GP surgery in Brighton from a private Whitehawk surgery is currently run by the Wellsbourne Healthcare Community Interest Company, but it could be handed over to Leeds-based One Medical Group after NHS Sussex started procuring for a new contract. NHS Sussex said it could not comment on the procurement process as it was still under way. Janet Sang, part of Sussex Defend NHS, said the campaign group was "extremely concerned" that an "effective and well-loved GP service" could be transferred to a profit-making entity. "We believe this is... not in the best interests of the people of Whitehawk," she added. One Medical Group, which said it had more than two decades of experience in "delivering high-quality primary care services across the UK", said it could not comment as the procurement process was ongoing. It added it had "consistently delivered [NHS services] to the highest standard across diverse demographics". "We pride ourselves on.... our collaborative approach with local communities, ensuring that healthcare is both reflective and responsive to local needs," it continued. 'Fantastic job' NHS Sussex said it needed to procure a new contract for running the doctor's surgery, which serves around 8,300 people, as the current one has expired. It said the new contract had been designed to meet the needs of the local population in what it called one of the most deprived areas in Sussex. Wellsbourne Healthcare CIC took over the GP surgery several years ago after the previous private provider walked away, according to the Local Democracy Reporting Service. Anger over uncertain future of GP surgery Brighton & Hove City Councillor David McGregor, who said he planned to attend the tug-of-war event, said the Wellsbourne Healthcare CIC had done a "fantastic job" and NHS Sussex should "reconsider".Chris Ward, Labour MP for Brighton Kemptown and Peacehaven, has started a petition - titled Save Wellsbourne Healthcare - that has more than 3,000 signatures as of 5 June. Sarah Webb, business manager at Wellsbourne Healthcare CIC, previously urged NHS Sussex to talk to the people of Whitehawk."Listen to residents," she told BBC Radio Sussex in May.
BBC News
an hour ago
- BBC News
King's Mill Hospital A&E wait times cut by 'Dragon's Den' idea
Waiting times in accident and emergency at Sutton-in-Ashfield's King's Mill Hospital have been reduced by moving some less seriously ill people to chairs instead of Forest Hospitals NHS Foundation Trust's executive board met on Thursday to discuss the effectiveness of a plan called Fit2Sit, which was introduced in January to tackle overcrowding and improve the flow of involves medics identifying which patients need assessment but do not need to be lying down on a trolley while they wait, with a separate room set aside to hold 19 Rose, lead nurse at King's Mill's A&E, said the staff-suggested idea had "dramatically reduced" overcrowding. The Local Democracy Reporting Service said the meeting was told the waiting time for non-admitted patients to be seen in A&E had dropped by about 40 minutes since the change – down from 196 minutes to 150 minutes. Meanwhile the average number of patients within the department's majors area, where patients need more intensive treatment, has dropped from 61 to 35.A total of 89% of patients are now offloaded by ambulance crews within 30 minutes of arrival, compared to 80% in December 2024. 'Suggested by staff' Richard Kemp, divisional director of nursing for urgent and emergency care at the trust, told the board: "We can keep our clinicians in consulting rooms [and] keep patients due an assessment in a private area."If necessary with ongoing investigation, a patient can return to the waiting room while that happens, whereas all of those patients would have been in the majors space previously, contributing to the crowding in that area."About £12,600 was spent on Fit2Sit from money raised by the trust's Daffodil Volunteers fund, including £5,000 awarded from a "Dragon's Den" initiative, which involves hospital staff pitching their own ideas to managers about how to solve chairman Graham Ward said: "The biggest positive is this came from our staff, their idea, their approach to how we can improve our patient experience."
